Form 4: Kymera CFO Sells Shares After Option Exercise

Kymera Therapeutics CFO Bruce N. Jacobs exercised stock options and subsequently sold 79,220 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, Inc. (KYMR), reported transactions on September 17, 2025.
• Jacobs exercised stock options to acquire 79,220 shares of common stock at an exercise price of $2.08 per share.
• Concurrently, Jacobs sold 79,220 shares of common stock at a weighted average price of $50.0048 per share.
• The sales occurred in multiple transactions with prices ranging from $49.90 to $50.25 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan established on September 6, 2024.
• Following these transactions, Jacobs beneficially owns 227,409 shares of common stock.
• The reported beneficial ownership includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025.
• The stock options exercised were fully vested and exercisable, with an expiration date of August 28, 2029.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction under a pre-arranged 10b5-1 plan, which is a common practice for executive compensation and liquidity management. It does not inherently signal positive or negative company-specific news.

Positives

• The Chief Financial Officer realized significant gains by exercising options at $2.08 and selling shares at an average of $50.0048, indicating personal financial success from company equity.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests a pre-scheduled, non-discretionary sale, mitigating concerns about immediate insider sentiment.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some investors as a reduction in insider exposure to the company's future performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction represents a routine liquidity event for a key executive. While it increases the float slightly, the impact on overall share price is typically minimal given the pre-arranged nature of the sale.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by the Chief Financial Officer under a pre-arranged 10b5-1 trading plan. Such transactions are common for executive compensation and personal financial planning and typically do not provide new material information to warrant a change in investment recommendation. The filing itself does not offer insights into the company's operational performance, strategic direction, or financial health that would influence a 'buy' or 'sell' decision.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, Bruce N. Jacobs, Chief Financial Officer, Equity Sales